Research shows new HIV strains resist drug-combination AIDS treatment

Article Abstract:

A research, conducted by Sabine Yerly and her colleagues at the University Hospital in Geneva, Switzerland, revealed that new HIV strains resist drug-combination therapies used in the treatment of AIDS. Speaking at the 12th World AIDS conference in Geneva, Yerly said that in a study of 57 newly-infected people, they found out that six showed resistance to the new protease inhibitor drugs that play a major role in the combination drug-therapies. Moreover, five of the of the newly-infected people showed resistance to AZT, Glaxo Wellcome PLC's drug for HIV that is commonly used in "cocktail" treatments. However, news of the drug-resistant strains were tempered by other reports that some patients who fared well for a long time on the combination drug therapy may someday be able to end the treatment.

Comment:

Switz: Research shows that new HIV strains resist drug-combination therapies used in the treatment of AIDS

Switzerland, Science & research, Immunology, Article

---

BT, Microsoft plan mobile net devices

Article Abstract:

Microsoft and British Telecommunications have agreed to jointly develop mobile phones that will provide Internet access, in addition to voice service. The deal deepens the partnership between the two companies. The planned products will use Microsoft's Windows CE operating system. The companies also plan to introduce multimedia services tied to the new phones.

United Kingdom, United States, Product development, Radio and Television Broadcasting and Wireless Communications Equipment Manufacturing, Mobile & Base Transceivers, Strategic alliances, Microsoft Corp., Wireless communications, Telecommunications equipment industry, Contracts, British Telecommunications PLC, Transceivers, Wireless communication systems

---

SARS research spurs patent race

Article Abstract:

International corporations and scientific groups have filed patent applications on the severe acute respiratory syndrome (SARS) and on its genetic makeup. The patents are intended to secure rights in any vaccine, drug, or medical test related to SARS.

Research and Testing Services, Medical Research, Epilepsy & Muscle Disease R&D, Patents & copyrights, Administration of Public Health Programs, Health Research Programs, Pharmaceutical industry, Vaccines industry, Biological products industry, Medical tests, Intellectual property, Medicine, Experimental, Severe acute respiratory syndrome

Similar abstracts:

• Abstracts: Where right is left: Ireland. Out for the count: Ireland. Yes and no
• Abstracts: European banks' earnings show signs of improving. S&P delays ratings on Landesbank debt
• Abstracts: A matter of trust. A national kick at the can. No sweat. The Phototypes database profiles consumers who have no trouble getting exactly what they want
• Abstracts: China misdials on cellphones. China's roaring economy shows signs of moderating: Beijing antitrust plan, competition report worry foreign firms
• Abstracts: Chinese leaders mull constitution overhaul. EU meets with its future at stake: leaders hope to bridge gap over nations' voting rights in draft of constitution

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.